About Dr. Khan
Arif Khan, M.D., Medical Director and Principal Investigator at NWCRC, is a Board Certified Psychiatrist and an Adjunct Professor of Psychiatry at Duke University School of Medicine. His specialty is psychiatry and the treatment of mood disorders.
Dr. Khan and the team at NWCRC have been researching schizophrenia in adults and adolescents for many years. He has been involved in over 15 clinical trials studying different medications for use in the treatment of schizophrenia. Some of the medications he has studied include Zyprexa®, Risperdal®, Seroquel® and Abilify®.
Dr. Khan has published papers about schizophrenia in medical and psychiatric journals around the world. You can view the abstracts to some of these articles by clicking on the links below.
Suicide risk in placebo versus active treatment in placebo-controlled trials for schizophrenia. Storosum J, van Zweiten B, Wohlfarth T, de Haan L, Khan A, van der Brink W. Archives of General Psychiatry 60(4): 365-368, 2003.
Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials. Khan A, Schwartz K, Stern C, Redding N, Kolts RL, Brown WA, Robinson D. Journal of Clinical Psychiatry, 68(12): 1828-1833, 2007.